Who are Nirogacestat oral tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LY450139.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nirogacestat-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nirogacestat oral tablet — Competitive Intelligence Brief

Nirogacestat oral tablet (Nirogacestat oral tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gamma-secretase inhibitor. Area: Oncology.

phase 3 Gamma-secretase inhibitor Gamma-secretase complex (PSEN1/PSEN2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nirogacestat oral tablet (Nirogacestat oral tablet) — SpringWorks Therapeutics, Inc.. Nirogacestat inhibits gamma-secretase, reducing the production of Notch intracellular domain and downstream signaling that drives abnormal cell proliferation in desmoid tumors.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nirogacestat oral tablet TARGET	Nirogacestat oral tablet	SpringWorks Therapeutics, Inc.	phase 3	Gamma-secretase inhibitor	Gamma-secretase complex (PSEN1/PSEN2)
LY450139	LY450139	Eli Lilly and Company	phase 3	Gamma-secretase inhibitor	Gamma-secretase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gamma-secretase inhibitor class)

Eli Lilly and Company · 1 drug in this class
SpringWorks Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nirogacestat oral tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/nirogacestat-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab